Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
IPO Year: 2015
Exchange: NYSE
Website: evolenthealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $15.00 | Buy | Needham |
| 12/3/2024 | $36.00 → $29.00 | Buy | BTIG Research |
| 11/8/2024 | $38.00 → $16.00 | Overweight → Equal-Weight | Stephens |
| 10/11/2024 | $35.00 | Overweight | KeyBanc Capital Markets |
| 8/9/2024 | $28.00 → $33.00 | Hold → Buy | Truist |
| 4/22/2024 | $40.00 | Buy | Citigroup |
| 3/1/2024 | $45.00 | Outperform | Oppenheimer |
| 1/3/2024 | $39.00 | Overweight | Barclays |
| 12/6/2023 | $37.00 | Mkt Outperform | JMP Securities |
| 10/16/2023 | $46.00 | Buy | UBS |
Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00
BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously
Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously
KeyBanc Capital Markets initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $35.00
Truist upgraded Evolent Health from Hold to Buy and set a new price target of $33.00 from $28.00 previously
Citigroup initiated coverage of Evolent Health with a rating of Buy and set a new price target of $40.00
Oppenheimer initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $45.00
Barclays initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $39.00
JMP Securities initiated coverage of Evolent Health with a rating of Mkt Outperform and set a new price target of $37.00
UBS initiated coverage of Evolent Health with a rating of Buy and set a new price target of $46.00